Rhythm (Nasdaq: IRTC) today announced new results supporting its Zio long-term continuous monitoring (LTCM) ECG patch.

Zio LTCM service was associated with the highest adjusted odds of a new arrhythmia encounter diagnosis compared to other ACM modalities and all other LTCM services. Compared to Holter monitors ...

For recording asymptomatic as well as symptomatic arrhythmias, a continuous recording device such as a Holter monitor or Zio Patch is preferable. The implanted loop recorder or diagnostic ...

Zio LTCM service was associated with the highest adjusted odds of a new arrhythmia encounter diagnosis compared to other ACM modalities and all other LTCM services. Compared to Holter monitors ...

Together, these findings highlight the benefits of Zio ® long-term continuous monitoring (LTCM) 2 and the limitations in 24–48-hour Holter monitoring still prevalent in current clinical ...

which says it is likely that Zio XT will be cost saving – or at least similar in cost – to Holter monitoring. “Throughout the COVID-19 pandemic we have seen a number of cardiac patients ...

Together, these findings highlight the benefits of Zio long-term continuous monitoring and the limitations in 24-48-hour Holter monitoring still prevalent in current clinical practices and payer ...

If reimbursement hurdles can be overcome, the traditional wired Holter monitor may be replaced by newer technologies, such as the Zio Patch.

64% Undetected in the First 48 Hours: Among daily-symptom patients—those with daily or greater symptom frequency— diagnosed with actionable arrhythmias, nearly two-thirds went undetected ...

“They reinforce the limitations of Holter-duration monitoring and highlight the value of Zio long-term continuous monitoring up to 14 days. Once again, iRhythm's real-world data are contributing ...